HealthInvest Partners AB Has $1.68 Million Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

HealthInvest Partners AB increased its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 127.4% during the third quarter, HoldingsChannel reports. The fund owned 54,060 shares of the company’s stock after acquiring an additional 30,282 shares during the quarter. Immunocore accounts for about 0.8% of HealthInvest Partners AB’s investment portfolio, making the stock its 27th biggest holding. HealthInvest Partners AB’s holdings in Immunocore were worth $1,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Exchange Traded Concepts LLC lifted its stake in Immunocore by 40.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after acquiring an additional 1,461 shares in the last quarter. Connective Portfolio Management LLC purchased a new stake in shares of Immunocore during the third quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Immunocore by 69.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the period. DNB Asset Management AS raised its position in Immunocore by 35.0% in the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after acquiring an additional 1,868 shares during the period. Finally, XTX Topco Ltd purchased a new position in Immunocore in the second quarter valued at about $303,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Price Performance

Immunocore stock traded down $0.16 during mid-day trading on Thursday, reaching $32.26. The stock had a trading volume of 4,178 shares, compared to its average volume of 513,782. Immunocore Holdings plc has a one year low of $29.72 and a one year high of $76.98. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The company has a 50-day moving average price of $32.34 and a two-hundred day moving average price of $37.94.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.59) earnings per share. As a group, equities analysts anticipate that Immunocore Holdings plc will post -0.94 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $72.00 to $38.00 in a research note on Monday, November 11th. Needham & Company LLC decreased their price objective on Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Oppenheimer reissued an “outperform” rating and issued a $89.00 price target (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Finally, Morgan Stanley dropped their target price on Immunocore from $80.00 to $74.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.18.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.